MUMBAI, India, July 25 -- Intellectual Property India has published a patent application (202527046524 A) filed by Prolong Pharmaceuticals Llc, South Plainfield, U.S.A., on May 14, for 'a stable hemoglobin protein composition.'
Inventor(s) include Pandya, Shaunak G; and Jubin, Ronald.
The application for the patent was published on July 25, under issue no. 30/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to a hemoglobin protein composition comprising biologically active hemoglobin and less than 2% methemoglobin (metHb) wherein the metHb is maintained below 2% after reoxygenation of hemoglobin. Furthermore, hemoglobin protein composition comprising biologically active hemoglobin and less than 25% of charge variants of total oxygenated hemoglobin. Moreover, the present invention also provides an effective concentration of antioxidant more than 5 mM used during heat treatment. The present invention provides pharmaceutically stable composition of hemoglobin. Furthermore, the present invention also provides a process for reducing and/or controlling the formation of metHb, charge variants and inactivation of viral and/or prion during manufacturing of oxygenated hemoglobin. In addition, the invention provides therapeutic use of oxygenated hemoglobin."
The patent application was internationally filed on Oct. 13, 2023, under International application No.PCT/US2023/076908.
Disclaimer: Curated by HT Syndication.
